Contact this trialFirst, we need to learn more about you.
PD-1 Inhibitor
RBN-2397 + Pembrolizumab for Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Baton Rouge, Louisiana
This trial will study RBN-2397, a new drug that inhibits an enzyme called PARP7, which is switched on by cancer stresses. Cancer cells use PARP7 to hide from the immune system, but RBN-2397 has been shown in animal and human studies to inhibit tumor growth and also shuts down the "don't kill me" signal the tumor is sending to evade the immune system. This trial will study whether RBN-2397 in combination with pembrolizumab (a PD-1 inhibitor) can restore the response to treatment in patients with SCCL who have been previously treated with a PD-
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.